LAUSR

Based on the positive outcomes of five randomised controlled trials [1–4], bronchoscopic lung volume reduction (BLVR) using endobronchial valves (Zephyr EBVs; PulmonX Corp., Redwood City, CA, USA) is now a treatment option for a subset of patients with severe emphysema [5]. Very few data are available regarding the relevance of a sequential, bilateral treatment using EBVs in patients with severe emphysema. Fiorelli et al. [6] reported in 2016 their experience with 14 patients treated contralaterally after loss of benefit (18 months median delay between both sides) and demonstrated that patients can recover similar functional parameters compared to outcomes obtained after the initial intervention. The same year, Trudzinski et al. Bilateral endobronchial valves treatment can lead to additional significant benefits in patients who respond to the first procedure and have a clear target lobe on both lungs but increases the rate of complications https://bit.ly/3J0mZ8h